SCHEMBL2685260

SCHEMBL2685260

Cc1cc(-c2ccc(O)c(NC(=O)[C@@H](N)Cc3ccccc3)c2)ccn1

nearest known ligand 0.53

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
▸ GPR142 Q7Z601 5/20 0.53
▸ WNT3A P56704 5/20 0.47
▸ PSEN1 P49768 3/20 0.47
▸ PSEN2 P49810 3/20 0.47
▸ APH1B Q8WW43 3/20 0.47
▸ NCSTN Q92542 3/20 0.47
▸ APH1A Q96BI3 3/20 0.47
▸ PSENEN Q9NZ42 3/20 0.47
▸ HDAC1 Q13547 3/20 0.46
▸ KDM4E B2RXH2 1/20 0.46
▸ APOBEC3A P31941 1/20 0.46
▸ GFER P55789 1/20 0.46
▸ APOBEC3G Q9HC16 1/20 0.46
▸ CIT O14578 1/20 0.46
▸ PORCN Q9H237 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2685421 0.87 GPR142 (0.68) GPR142HDAC1KDM4EAPOBEC3AGFER
SCHEMBL2685425 0.87 GPR142 (0.68) GPR142HDAC1KDM4EAPOBEC3AGFER
SCHEMBL2686723 0.83 GPR142 (0.47) GPR142WNT3APSEN1PSEN2APH1B
SCHEMBL2686712 0.83 GPR142 (0.47) GPR142WNT3APSEN1PSEN2APH1B
SCHEMBL2684336 0.83 GPR142 (0.53) GPR142WNT3APSEN1PSEN2APH1B
SCHEMBL2686772 0.79 GPR142 (0.51) GPR142WNT3APSEN1PSEN2APH1B
SCHEMBL2685002 0.79 GPR142 (0.51) GPR142WNT3APSEN1PSEN2APH1B
SCHEMBL2686777 0.79 GPR142 (0.77) GPR142
SCHEMBL6032434 0.78 GPR142 (0.44) GPR142WNT3APSEN1PSEN2APH1B
SCHEMBL15875890 0.78 GPR142 (0.44) GPR142WNT3APSEN1PSEN2APH1B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8785468-B2 Phenylalanine amide derivatives useful for treating insulin-related diseases and conditions AMGEN INC. (US) 2014-07-22 — — US disclosed
US-8785468-B2 Phenylalanine amide derivatives useful for treating insulin-related diseases and conditions AMGEN INC. (US) 2014-07-22 — — US disclosed
US-20120115811-A1 PHENYLANALINE AMIDE DERIVATIVES USEFUL FOR TREATING INSULIN-RELATED DISEASES AND CONDITIONS AMGEN INC. (US) 2012-05-10 — — US disclosed
US-20120115811-A1 PHENYLANALINE AMIDE DERIVATIVES USEFUL FOR TREATING INSULIN-RELATED DISEASES AND CONDITIONS AMGEN INC. (US) 2012-05-10 — — US disclosed
WO-2010093849-A2 PHENYLALANINE AMIDE DERIVATIVES USEFUL FOR TREATING INSULIN-RELATED DISEASES AND CONDITIONS AMGEN INC. (US) 2010-08-19 — — WO disclosed
WO-2010093849-A2 PHENYLALANINE AMIDE DERIVATIVES USEFUL FOR TREATING INSULIN-RELATED DISEASES AND CONDITIONS AMGEN INC. (US) 2010-08-19 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120115811-A1 PHENYLANALINE AMIDE DERIVATIVES USEFUL FOR TREATING INSULIN-RELATED DISEASES AND CONDITIONS IAPP, INSR, AMY2A GPR142 2779/4885WNT3A 4600/4885PSEN1 703/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback